The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study

BACKGROUND: Chronic myeloid leukemia is associated with a BCR/ABL oncoprotein inhibited by imatinib mesylate, the first tyrosine kinase inhibitor. Although experimental studies have clearly demonstrated the efficacy of imatinib, up-to-date data on its effectiveness at the population level are limite...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Felice, Enza, Roncaglia, Francesca, Venturelli, Francesco, Mangone, Lucia, Luminari, Stefano, Cirilli, Claudia, Carrozzi, Giuliano, Giorgi Rossi, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219019/
https://www.ncbi.nlm.nih.gov/pubmed/30400842
http://dx.doi.org/10.1186/s12885-018-4984-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219019/
https://www.ncbi.nlm.nih.gov/pubmed/30400842
http://dx.doi.org/10.1186/s12885-018-4984-3

Ejemplares similares